Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: Clinical and molecular analyses of a phase 3 study

Paola Tacchetti, Carolina Terragna, Monica Galli, Elena Zamagni, Maria Teresa Petrucci, Annalisa Pezzi, Vittorio Montefusco, Marina Martello, Patrizia Tosi, Luca Baldini, Jacopo Peccatori, Miriana Ruggieri, Lucia Pantani, Antonio Lazzaro, Francesca Elice, Serena Rocchi, Alessandro Gozzetti, Guido Cavaletti, Antonio Palumbo, Michele Cavo

Research output: Contribution to journalArticlepeer-review

Abstract

A subanalysis of the GIMEMA-MMY-3006 trial was performed to characterize treatment-emergent peripheral neuropathy (PN) in patients randomized to thalidomide-dexamethasone (TD) or bortezomib-TD (VTD) before and after double autologous transplantation (ASCT) for multiple myeloma (MM). A total of 236 patients randomized to VTD and 238 to TD were stratified according to the emergence of grade ≥2 PN. Gene expression profiles (GEP) of CD138+ plasma cells were analyzed in 120 VTD-treated patients. The incidence of grade ≥2 PN was 35% in the VTD arm and 10% in the TD arm (P

Original languageEnglish
Pages (from-to)1085-1091
Number of pages7
JournalAmerican Journal of Hematology
Volume89
Issue number12
DOIs
Publication statusPublished - Dec 1 2014

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: Clinical and molecular analyses of a phase 3 study'. Together they form a unique fingerprint.

Cite this